Changes

Jump to: navigation, search

Backup

7,618 bytes added, 13:47, 16 February 2012
/* Methodology */
*A merger may result in financial synergy and benefits for the firm in many ways:-
 
**By eliminating financial constraints
**By enhancing debt capacity. This is because a merger of two companies can bring stability of cash flows which in turn reduces the risk of insolvency and enhances the capacity of the new entity to service a larger amount of debt
*Limiting the severity of competition by increasing the company's market power. A merger can increase the market share of the merged firm. This improves the profitability of the firm due to economies of scale. The bargaining power of the firm vis-à-vis labour, suppliers and buyers is also enhanced. The merged firm can exploit technological breakthroughs against obsolescence and price wars.
'''Note:''' In this research report, researcher considered two following objective of merger and acquisition:
#To Enter in emerging markets
===Methodology===
* '''Step 1''': First, list all the players present in Ureteral Stent Market were identified.(The list of companies was retrieved from the FDA site from Registration & Listing database) 
** Number of companies that were identified in this step: 20
* '''Step 2''': The second step involved identifying and eliminating companies that are large, and established players or the subsidiaries of the big players in the industry.  
**Number of companies eliminated in this step: 14
**Number of (small) companies of interest left: 6
* '''Step 3''': Once the large, and established players were eliminated, companies were compared based on various parameters and rated on the scale of 5 to identify the best target. Please check the following table and dashboard: 
**Number of potential target companies: 6
<br/>
{|border="2" cellspacing="0" cellpadding="4" width="80%" align="center"
|align = "center" bgcolor = "#4F81BD"|<font color="#FFFFFF">'''Company'''</font>
|align = "center" bgcolor = "#4F81BD"|<font color="#FFFFFF">'''Headquartered'''</font>
|align = "center" bgcolor = "#4F81BD"|<font color="#FFFFFF">'''Stent Details'''</font>
|align = "center" bgcolor = "#4F81BD"|<font color="#FFFFFF">'''Company Type'''</font>
|align = "center" bgcolor = "#4F81BD"|<font color="#FFFFFF">'''2010 Revenue (Mn)'''</font>
|align = "center" bgcolor = "#4F81BD"|<font color="#FFFFFF">'''No of Employees'''</font>
|align = "center" bgcolor = "#4F81BD"|<font color="#FFFFFF">'''Geographical Revenue Share'''</font>
|align = "center" bgcolor = "#4F81BD"|<font color="#FFFFFF">'''R&D investment (Mn)'''</font>
|align = "center" bgcolor = "#4F81BD"|<font color="#FFFFFF">'''No. of Patent'''</font>
|align = "center" bgcolor = "#4F81BD"|<font color="#FFFFFF">'''Technology Focus'''</font>
|-
|bgcolor = "#DBE5F1"|Applied Medical Resources Corp.
|bgcolor = "#DBE5F1"|USA
|bgcolor = "#DBE5F1"|Mesh ureteral stent<br>C-flex ureteral stent<br>Silicone ureteral stent<br>Tethered ureteral stent<br>C-flex ureteral stent<br>Ureteral stent<br>Silhouette pediatric stent
|bgcolor = "#DBE5F1"|Manufacturer
|align = "center" bgcolor = "#DBE5F1"|$282
|align = "center" bgcolor = "#DBE5F1"|1900
|bgcolor = "#DBE5F1"|USA: 62%<br>Asia: 32%<br>Rest of World: 6%
|bgcolor = "#DBE5F1"|$38.3 (13%)
|align = "center" bgcolor = "#DBE5F1"|212
|bgcolor = "#DBE5F1"|High
|-
|Bioteque Corp.
|Taiwan
|Bioteque Double Pigta
|Contract Manufacturer; Contract Sterilizer; Manufacturer
|align = "center"|$27.85
|align = "center"|350
|Taiwan: 100%
|$1.4 (5%)
|align = "center"|16
|Medium
|-
|bgcolor = "#DBE5F1"|Hobbs Medical, Inc.
|bgcolor = "#DBE5F1"|USA
|bgcolor = "#DBE5F1"|HM Ureteral Double Pigtail Stent
|bgcolor = "#DBE5F1"|Manufacturer
|align = "center" bgcolor = "#DBE5F1"|$2.30
|align = "center" bgcolor = "#DBE5F1"|22
|bgcolor = "#DBE5F1"|USA: 97.2%<br>Japan: 2.3%<br>Others: 0.5%
|bgcolor = "#DBE5F1"|$0.06 (2.87%)
|align = "center" bgcolor = "#DBE5F1"|1
|bgcolor = "#DBE5F1"|Low
|-
|Lake Region Medical Limited
|Ireland
|M-Wires
|Contract Manufacturer
|align = "center"|$84.86
|align = "center"|611
|Europe: 68%<br>USA: 21%<br>Others: 11%
|$8.48 (3.85%)
|align = "center"|8
|Medium
|-
|bgcolor = "#DBE5F1"|Martech Medical Products
|bgcolor = "#DBE5F1"|USA
|bgcolor = "#DBE5F1"|Ureteral Stent
|bgcolor = "#DBE5F1"|Contract Manufacturer
|align = "center" bgcolor = "#DBE5F1"|$23.00
|align = "center" bgcolor = "#DBE5F1"|180
|bgcolor = "#DBE5F1"|USA: 78.3%<br>Europe: 12.7%<br>Others: 9%
|bgcolor = "#DBE5F1"|$1.1 (4.79%)
|align = "center" bgcolor = "#DBE5F1"|0
|bgcolor = "#DBE5F1"|Low
|-
|Allium Medical
|Israel
|URS - Ureteral Stent<br>TPS - Triangular Prostatic Stent<br>BUS - Bulbar Urethral Stent<br>RPS - Round Posterior Urethral Stent<br>BIS - Biliary Stent
|Manufaturer
|align = "center"|$2.04
|align = "center"|20
|Domestic: 88.6%<br>International: 11.4%
|$0.082 (4%)
|align = "center"|2
|Low
|-
|}<br clear="all">
'''Note:''' Data for Geographical segment, R&D expenditure and Technology focus has been masked.
* Step 4{|align="center"|<gflash>1000 750 http: Finally, after an in-depth analysis of the potential target companies’ on various parameters, following companies identified to be best possible target companies//dolcera.com/upload/files/ranking1.swf</gflash>|-|}<br/>
 * '''Step 4''': Finally, after an in-depth analysis of the potential target companies’ on various parameters, following companies identified to be best possible target companies.**To improve Product Portfolio : '''Applied Medical Resources Corp.'''**To enter in Emerging Markets : '''Bioteque Corp.'''
===Company Profile===
====Applied Medical Resources Corp.====
{|border="2" cellspacing="0" cellpadding="4" width="60%" align="center"|bgcolor = "#376091" colspan = "2"|<font color="#FFFFFF">'''APPLIED MEDICAL RESOURCES CORP.'''</font>|-|bgcolor = "#C5D9F1"|'''Revenues'''|bgcolor = "#C5D9F1"|2010: $280 million|-|'''Net profit (2010)'''|$20.89 million|-|bgcolor = "#C5D9F1"|'''R&D Investment'''|bgcolor = "#C5D9F1"|2010: $ 38.3 million (13% of revenues)|-|'''Number of employees'''|1900|-|bgcolor = "#C5D9F1"|'''Year Established'''|bgcolor = "#C5D9F1"|1987|-|'''Headquarters'''|USA|-|bgcolor = "#C5D9F1"|'''Key People'''|bgcolor = "#C5D9F1"|CEO: Said S. Hilal|-|'''Products & Technology'''|Specialty Areas:Cardiac/Vascular, Colorectal, GYN, Urology <br>New Products:Epix (Laparoscopic Intrumentation), GelPOINT (Advanced Access Platform), Kii Fios (First EntrySystem)|-|bgcolor = "#C5D9F1"|'''Products in Ureteral Stent'''|bgcolor = "#C5D9F1"|C-flex ureteral stent, Silicone ureteral stent, Tethered ureteral stent, C-flex ureteral stent, Ureteral stent<br>Silhouette pediatric stent|-|'''Geographical revenue breakdown (2010)'''|USA: $182.70 million (65%)<br>Others: $99.47 million (35%)|-|bgcolor = "#C5D9F1"|'''Company Overview'''|bgcolor = "#C5D9F1"|Applied Medical Resources Corporation is a new generation medical device company founded in 1987 and headquartered in Southern California. It is involved in developing, manufacturing and marketing of innovative products for Minimally Invasive Surgery, Cardiac, Vascular, Urological, Colorectal, Bariatric, Obstetric, Gynecologic and General Surgery. The product portfolio covers 25 technologies and more than 700 products. The company has spread its business globally across 75 countries including Africa, Middle East,Americas, Caribbean, Asia, Australia and Europe through its network of international distributors.|-|}
====Bioteque Corp.====
 
{|border="2" cellspacing="0" cellpadding="4" width="60%" align="center"
|bgcolor = "#376091" colspan = "2"|<font color="#FFFFFF">'''Bioteque Corp.'''</font>
|-
|bgcolor = "#C5D9F1"|'''Revenues'''
|bgcolor = "#C5D9F1"|2010: $27.85 million
|-
|'''Net profit (2010)'''
|$20.89 million
|-
|bgcolor = "#C5D9F1"|'''R&D Investment'''
|bgcolor = "#C5D9F1"|2010: $38.3 million (13% of revenues)
|-
|'''Number of employees'''
|350
|-
|bgcolor = "#C5D9F1"|'''Year Established'''
|bgcolor = "#C5D9F1"|1991
|-
|'''Headquarters'''
|Taiwan
|-
|bgcolor = "#C5D9F1"|'''Key People'''
|bgcolor = "#C5D9F1"|
|-
|'''Products & Technology'''
|<br> NEPHROLOGY, UROLOGY, RADIOLOGY, CARDIOLOGY, RESPIRATORY CARE<br> CRITICAL CARE, IV ADMINISTRATION THERAPY, MOLDING PARTS
|-
|bgcolor = "#C5D9F1"|'''Products in Ureteral Stent'''
|bgcolor = "#C5D9F1"|C-flex ureteral stent, Silicone ureteral stent, Tethered ureteral stent, C-flex ureteral stent, Ureteral stent<br>Silhouette pediatric stent
|-
|'''Geographical revenue breakdown (2010)'''
|NA
|-
|bgcolor = "#C5D9F1"|'''Company Overview'''
|bgcolor = "#C5D9F1"|Bioteque Corporation manufactures and sells medical devices in Taiwan. It offers medical disposables for use in hemodialysis access, endovascular treatment, and other fields. It offers blood tubing lines, AVF needles, transducer protectors, and on line HDF with check valves or without check valves; IV infusion bags, precision IV infusion sets, drainage bags, insufflation tubing sets/filters, and various surgical drainage tubes; a range of medical components, which comprise blood tubing line components, percutaneous drainage components, infusion bag components, AVF needle components, precision IV infusion set components, and IV infusion bag components; a range of thermoplastic polyurethane catheters, including pigtail drainage catheter sets, double pigtail ureteral stent sets, biliary drainage catheters, percutaneous nephrostomy kits, and dialysis catheters; and other medical disposable products, such as closed suction catheters and artificial nose. The company also provides endovascular products, which consist of percutaneous transluminal coronary angioplasty, percutaneous transluminal angioplasty, angiography catheters, guiding catheters, sheath introducers, MRI/CT/angiography syringes, micro catheters, and hydrophilic coated guidewires. Bioteque Corporation was founded in 1991 and is based in Taipei, Taiwan.
|-
|}
==M&A Due Diligence Process==